

Program 12th International Workshop on Waldenstrom's Macroglobulinemia October 17-19, 2024, Prague, Czech Republic

Wednesday, October 16, 2024

[16:00-18:00] Early Registration

[18:00-20:00] Welcome Reception

DAY 1

Thursday, October 17, 2024

[7:45-8:00] Welcome to IWWM-12

Christian Buske, Jeffrey Matous, and Steven Treon [Workshop Organizers]

[8:00-9:00] Session I

WM Predisposition

Romanos Sklavenitis-Pistofidis, Merav Leiba [Chairs]

Findings from the iSTOP Study

Sigurdur Kristinsson, Landspitali-The National University Hospital of Iceland, Iceland

Large scale GWAS illuminates disease aetiology for WM and LPL Sonja Berndt, National Institutes of Health, USA

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in WM Compared to IgM-MGUS
Stephen Ansell, Mayo Clinic, United States

Multi-Omics for Deciphering Mechanisms of Progression in Pre-Malignant IgM Gammopathies Simone Ferrero, Università di Torino/Ematologia Universitaria, Italy

[8:45] Panel Discussion, All Session I Speakers

[9:00-10:00] Session II

WM/LPL Genomics I

Bruno Paiva, Christopher Oakes [Chairs]

Using Mutographs to Define the Molecular Landscape and Cell of Origin of WM Gareth Morgan, N.Y.U. Grossman School of Medicine, United States

Aberrant Expression of Spliced WNK2 Is an Early event in MYD88-Mutated WM that Activates ERK 1/2 and supports Tumor Growth

Maria Luisa Guerrera, Dana Farber Cancer Institute, United States

Molecular Clusters and Tumor-immune Drivers of IgM Monoclonal Gammopathies Patrizia Mondello, Mayo Clinic, United States

Clonal Architecture and Evolutionary History of WM at the Single-cell Level Cristina Jiménez, Hospital Universitario de Salamanca, Spain

Chromatin Accessibility Landscape and Regulatory Networks of IgM monoclonal Gammopathies David Moreno, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

[9:50] Panel Discussion, All Session II Speakers

[10:00-10:30] Mid-Morning Break & Networking

[10:30-11:30] Session III

WM/LPL Genomics II

Nikhil Munshi, Marzia Varettoni [Chairs]

Harnessing Epigenetic Signatures for Classification of WM Christopher Oakes, Ohio State University, James Comprehensive Cancer Center, United States

Landscape of IgH Gene Repertoire and Clinical Relevance to LPL/WM

Mu Hao, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital, China

Single Cell multi-omics for minimally invasive assessment of Treatment efficacy in WM Bruno Paiva, Clinica Universidad de Navarra, Spain

Clonal Hematopoiesis in Patients with WM Adam Sperling, Dana Farber Cancer Institute, United States

[11:15] Panel Discussion, All Session III Speakers

[11:30-12:30] Session IV

Single Cell RNA Analysis

Irene Ghobrial/Bruno Paiva [Chairs]

Single-Cell RNA Analysis of Tumor and Immune Cells in Asymptomatic WM
Romanos Sklavenitis-Pistofidis, Harvard Medical School, Broad Institute of MIT & Harvard, United States

Single-Cell RNA Analysis of MYD88 Mutated and Wild-type WM
Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece

Single-Cell RNA reveals Stem Cell like Subsets in WM Progression Xinxin Cao, Peking Union Medical College Hospital, China

Single-Cell RNA reveals Tumor Heterogeneity and Immunosuppressive Microenvironment in WM Hao Sun, Dana Farber Cancer Institute, United States

[12:15] Panel Discussion, All Session IV Speakers

[12:30-13:30] LUNCH

[13:30-14:30] Session V

Keynote Lectures

Sub-typing WM by Multi-Omic Analysis

Keynote Moderator: Christian Buske

Keynote Speaker: Zachary Hunter, Dana Farber Cancer Institute, United States

[13:50] Topic Discussion

BM Stromal Cells and Transcriptional Regulation: Lessons for WM

Keynote Moderator: Christian Buske

Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, United States

[14:20] Topic Discussion

[14:30-15:15] Session VI

Molecular Diagnostics in WM

Ramón García Sanz/Roman Hajek [Chairs]

Clinical Implications of Genomic Profiling

Carlos Fernandez de Larrea Rodríguez, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

Digital Droplet (ddPCR) for Detection of MYD88 L265P Variants

Daniela Drandi, Università di Torino/Ematologia Universitaria, Italy

Molecular Remissions is an Independent Predictor of Progression-Free Survival in WM Marzia Varettoni, Fondazione IRCCS Policlinico San Matteo, Italy

[15:00] Panel Discussion, All Session VI Speakers

[15:15-15:45] Mid-Afternoon Break & Networking

[15:45-16:30] Session: VII

Keynote Lecture

MYD88 and CXCR4 Signaling Cascades

Keynote Moderator: Adrian Wiestner, NHLBI, NIH, Hematology Branch, United States

Keynote Speaker: Steven Treon, Dana Farber Cancer Institute, United States

[16:15] Topic Discussion

[16:30-17:45] Session: VIII

Plenary Session I

Gareth Morgan, Zachary Hunter [Chairs]

Genomic Landscape of IgM MGUS and Stable vs. Progressive Asymptomatic WM Patients Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece

Single Cell Multi-omics for Phenotypic Characterization of Clonal B Cells in Patients with IGM MGUS and WM Carmen González Díaz-Cano, Universidad de Navarra, Spain

Characterization of WM/LPL using Single Cell Transcriptomic Analysis Minghao Dang, MD Anderson Cancer Center, United States

A Multi-omic Analysis of WM Defines Three Subtypes of Disease
Dylan Gagler, Perlmutter Cancer Center, NYU Langone Health, United States

Determining the Mutational Landscape of WM by Liquid Biopsy: Results of the ECWM-2 Trial Philipp Nakov, Universitätsklinikum Schleswig-Holstein, Germany

[17:40] Panel Discussion, All Session VIII Speakers

[19:00] Opening Ceremonies and Awards Presentation [18:15] Buses begin departing from the Hotel

- Keynote Speaker: BeiGene, Inc.
- Presentation of Jan Gosta Waldenstrom Awards
- Presentation of Robert A. Kyle Awards

DAY 2

Friday, October 18, 2024

[8:00-9:00] Session IX

Tumor Immune Microenvironment
Stephen Ansell & José Martínez Climent [Chairs]

Dysfunctions of Innate and Adaptive Immune Tumor Microenvironment in WM Jana Jakubikova, Cancer Research Institute, Biomedical Research Center SAS, Slovakia

Deciphering the Immune Microenvironment in WM Aldo Roccaro, ASST Spedali Civili di Brescia, Italy

Analysis of Molecular and Microenvironment Landscape and Its Role in Drug Resistance in WM Damien Roos-Weil, Sorbonne University, Groupe hospitalier Pitié-Salpêtrière, France

The Characterization and Modeling of MYD88 L265P Mutation and Chromosome 6q Deletion in Murine B-Cells Ruben Carrasco, Dana Farber Cancer Institute, United States

[8:45] Panel Discussion, All Session IX Speakers

[9:00-10:00] Session X

Chemoimmunotherapy in WM I Shirley D'Sa & M.J. Kersten [Chairs]

Dexamethasone, Rituximab, and Cyclophosphamide (DRC) versus Bortezomib-DRC (B-DRC) in WM Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

Long-term Outcomes of FILO Study: Frontline Benda-Rituximab in WM Veronique Leblond, Hôpital Pitié Salpêtrière,France

Multicenter Observational Study of Benda-Rituximab vs. RCD Francesco Autore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy

Long-term Outcomes of 678 patients with Symptomatic WM Elham Askari, Hospital Universitario Fundación Jiménez Díaz, Spain

[9:45] Panel Discussion, All Session X Speakers

[10:00-10:30] Mid-Morning Break & Networking

[10:30-11:30] Session XI

Chemoimmunotherapy in WM II

Veronique Leblond & Meletios Dimopoulos [Chairs]

Role of Proteasome Inhibitors in WM M.J. Kersten, University of Amsterdam, The Netherlands

Management of Transformed WM Eric Durot, Hopital Robert Debre, Hematologie Clinique, France

Final Analysis of Innovative Study; Ibrutinib Rituximab vs. Placebo/Rituximab: Clinical and Genomic Findings Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

Comparative Outcomes of Benda-R vs. Ibrutinib in Frontline WM Jithma Abeykoon, Mayo Clinic, United States

[11:15] Panel Discussion, All Session XI Speakers

[11:30-12:30] Session XII

BTK-Inhibitors in WM I

Stathis Kastritis & Marek Trneny [Chairs]

Long Term Findings of ASPEN Study: Clinical Outcomes
Meletios Dimopoulos, University of Athens School of Medicine, Greece

Long Term Updates on Ibrutinib and Venetoclax in Frontline WM Jorge Castillo, Dana Farber Cancer Institute, United States

ECWM-2 Prospective Study

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

BRAWM Study: Bendamustine, Rituximab and Acalabrutinib in Frontline WM Neil Berinstein, Odette Cancer Center, Canada

[12:15] Panel Discussion, All Session XII Speakers

[12:30-13:30] IWWM12 LUNCH

Moravia Hall

[12:30-13:30] Young Investigator Mentoring LUNCH Studio G

[13:30-14:30] Session: XIII

BTK-Inhibitors in WM II

Alessandra Tedeschi & Ranjana Advani [Chairs]

Pirtobrutinib in Relapsed/Refractory WM: Results from Bruin Study M. Lia Palomba, Memorial Sloan-Kettering Cancer Center, United States

Tirabrutinib in Symptomatic WM and Bing-Neel Syndrome (BNS)
Naohiro Sekiguchi, National Hospital Organization Disaster Medical Center ,Japan

Orelabrutinib in Relapsed/Refractory WM: Long-Term Follow-up Xinxin Cao, Peking Union Medical College Hospital, China

Prospective Study of Acalabrutinib and Rituximab in Symptomatic Anti-MAG mediated IgM Peripheral Neuropathy Shayna Sarosiek, Dana Farber Cancer Institute, United States

[14:15] Panel Discussion, All Session XIII Speakers

[14:30-15:00] Session XIV

Keynote Lecture

Utility of MRD in Clinical Care and New Drug Development in Myeloma

Keynote Moderator: Steven Treon, Dana Farber Cancer Institute, United States **Keynote Speaker:** Kenneth Anderson, Dana Farber Cancer Institute, United States **[14:50]** Topic Discussion

[15:00-16:00] Session: XV

BTK-I Intolerant and Resistant Disease

Carlos Fernández de Larrea Rodríguez & Prashant Kapoor [Chairs]

Dose reduction following ibrutinib intolerance in WM patients Shayna Sarosiek, Dana Farber Cancer Institute, United States

Zanubrutinib for Patients intolerant of other BTK-I Mazyar Shadman, Fred Hutchinson Cancer Research Center, United States

Bortezomib for Patients Failing BTK-I

Jahanzaib Khwaja, University College London Hospitals, United Kingdom

BGB-16673 BTK Degrader

John Seymour, Peter MacCallum Cancer Centre, Australia

[15:45] Panel Discussion, All Session XV Speakers

[16:00-17:00] Session XVI

Keynote Lectures

Genomic Evolution and Resistance Following BTK-Inhibitors in CLL:

Lessons for Sequencing and Managing BTK-Inhibitors

Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, United States **Keynote Speaker:** Jennifer Brown, Dana Farber Cancer Institute, United States **[16:20]** Topic Discussion

Role of BTK Inhibitors as Facilitators of Cellular Immunotherapies

Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, United States **Keynote Speaker:** Adrian Wiestner, NHLBI, NIH, Hematology Branch, United States **[16:50]** Topic Discussion

[17:00-19:00] Session XVII

IWWM12 Poster Highlights
Andrew Branagan & Josephine Vos [Chairs]
Poster Session & Reception
Moravia Hall

[19:30] Faculty Dinner Reception

[19:00] Departure in the Hotel Lobby

DAY 3

Saturday, October 19, 2024

[8:00-9:00] Session XVIII

Special Topics Lectures

Moshe Gat & Claudio Cerchione [Chairs]

Management of IgM De-Myelinating neuropathy

Speaker: Shirley D'Sa, UC London Hospitals NHS, United Kingdom

Management of Bing Neel Syndrome

Speaker: Monique Minnema, University of Utrecht, The Netherlands

Diagnostic Workup and Management of WM-related Amyloid

Speaker: Giampaolo Merlini, University of Pavia, Italy

Diagnostic Workup and Management of Monoclonal IgM-related Cold Agglutinin Disease

Speaker: Josephine Vos, University of Amsterdam, The Netherlands

[8:45] Panel Discussion, All Session XVIII Speakers

[9:00-10:00] Session: XIX

Plenary Session II

Ranjana Advani & Meletios Dimopoulos [Chairs]

Phase I Study of the Novel BCL2 Inhibitor Sonrotoclax in Relapsed/Refractory WM Ramón García Sanz, University Hospital Gregorio Marañón, Spain

Zanubrutinib in Bing Neel Syndrome: Efficacy and Tolerability
Anne-Marie Becking, Amsterdam UMC, The Netherlands

Real World Outcomes of ASCT in Patients with WM: Report from LWP EBMT Charalampia Kyriakou, University College London Hospitals NHS Trust, United Kingdom

Novel BiFunctional HCK/BTK Protacs for MYD88 Mutated WM and ABC DLBCL John M. Hatcher, Dana Farber Cancer Institute, United States

[9:45] Panel Discussion, All Session XIX Speakers

[10:00-10:30] Mid-Morning Break & Networking

[10:30-12:30] Session XX

Great Debates in WM
Eva Kimby & Irene Ghobrial [Chairs]

[10:30-11:00] Great Debate I

What should be the Standard for Frontline Treatment for WM?

For Bendamustine plus Rituximab

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. of Internal Medicine III, Germany

For Cyclophosphamide, Dexamethasone, Rituximab (CDR)

Stathis Kastritis, National and Kapodistrian University of Athens, Greece

For BTK-inhibitors

Alessandra Tedeschi, A. O. Ospedale Niguarda Ca' Granda, Italy

[11:00-11:30] Great Debate II

What is the optimal approach for frontline use of BTK-inhibitors in WM?

For Limited Duration Combination Therapy with BTK-inhibitors in WM

Neil Berinstein, Odette Cancer Center, Canada

For Continuous Administration of BTK-inhibitors as Monotherapy

Prashant Kapoor, Mayo Clinic, United States

[11:30-12:00] Great Debate III

What is the next best treatment for WM patients progressing on covalent BTK-inhibitors? For Pirtobrutinib

M. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

For Venetoclax

Jorge Castillo, Dana Farber Cancer Institute, United States

[12:00-12:30] Great Debate IV

Should TP53 Alterations be Considered for Treatment Decision Making in WM Patients?

Yes, TP53 Alterations should be considered

Ramón García Sanz, University Hospital Gregorio Marañón, Spain

No, TP53 Alterations should not considered

Shirley D'Sa, University College London Hospitals NHS Trust, United Kingdom

[12:30-13:30] LUNCH

[13:30-14:30] Session XXI

Novel Drug Development for WM Ramón García Sanz & Lu-Gui Qiu [Chairs]

Development of IRAK1/IRAK4 Bifunctional PROTACs (Proteolysis-Targeting Chimeras) for MYD88 mutated WM Sara Buhrlage, Dana Farber Cancer Institute, United States

Pacritinib is a Highly Potent Inhibitor of HCK and IRAK and Triggers High Levels of Apoptosis in WM Shirong Liu, Dana Farber Cancer Institute, United States

Pre-clinical Models for Prediction of Immunotherapy Outcomes and Immune Evasion Jose Martínez Climent, University of Navarra, Spain

Development of BTK/BTK -IKZF Protacs for B-Cell Malignancies Paula O'Connor, Nurix Therapeutics, Inc., United States

[14:15] Panel Discussion, All Session XXI Speakers

[14:30-15:30] Session XXII

Clinical Trials in Progress for WM I
Jeffrey Matous & Shayna Sarosiek [Chairs]

Carfilzomib With and Without Ibrutinib in Frontline and Relapsed/Refractory WM (CZAR-1) Meletios Dimopoulos, University of Athens School of Medicine, Greece

Rainbow Trial: Ibrutinib Rituximab vs. DRC in Newly Diagnosed WM Rebecca Auer, Barts Health NHS Trust, United Kingdom

Zanubrutinib plus Benda-R in Newly diagnosed WM Shuhua Yi, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), China

Pirtobrutinib and Venetoclax in Relapsed or Refractory WM Jorge Castillo, Dana Farber Cancer Institute, United States

[15:15] Panel Discussion, All Session XXII Speakers

[15:30-16:00] Mid-Afternoon Break & Networking

[16:00-17:00] Session XXIII

Clinical Trials in Progress for WM II Efstathios Kastritis & Prashant Kapoor [Chairs]

Loncastuxumab in Relapsed/Refractory WM
Shayna Sarosiek, Dana Farber Cancer Institute, United States

Sonrotoclax for Relapsed/Refractory WM

Jeffrey Matous, Colorado Blood Cancer Institute, United States

Multi-center Trial of Ipofosine in Relapsed/Refractory WM Andrei Shustov, Cellectar Biosciences, United States

CD20-Directed CAR-T Cell

Mazyar Shadman, Fred Hutchinson Cancer Res Center, United States

[16:45] Panel Discussion, All Session XXIII Speakers

[17:00-18:00] Session XXIV

Clinical Trials in Progress for WM III Roger Owen & Pierre Morel [Chairs]

WM-NET Clinical Trial Priorities

Jorge Castillo, Dana Farber Cancer Institute, United States

Gottfried von Keudell, Beth Israel Deaconess Medical Center, United States

ECWM Clinical Trial Priorities

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

[19:00] Dinner Reception and Closing Ceremonies

[18:15] Buses begin departing from the Hotel

- Presentation of Peter S. Bing Humanitarian Awards
- Presentation of the Young Investigator Awards
- Announcement and Welcome to IWWM-13